Multi-laboratory evaluation of immunoaffinity LC-MS-based glucagon-like peptide-1 assay

Bioanalysis. 2023 Feb;15(4):207-218. doi: 10.4155/bio-2022-0240. Epub 2023 Mar 24.

Abstract

Background: Although the fit-for-purpose approach has been proposed for biomarker assay validation, practical data should be compiled to facilitate the predetermination of acceptance criteria. Methods: Immunoaffinity LC-MS was used to analyze glucagon-like peptide-1 as a model biomarker in six laboratories. Calibration curve, carryover, parallelism, precision, relative accuracy and processed sample stability were evaluated, and their robustness among laboratories was assessed. The rat glucagon-like peptide-1 concentrations in four blinded samples were also compared. Results: The obtained results and determined concentrations in the blinded samples at all laboratories were similar, with a few exceptions, and robust, despite the difference in optimization techniques among laboratories. Conclusion: The results provide insights into the predefinition of the acceptance criteria of immunoaffinity LC-MS-based biomarker assays.

Keywords: biomarker assay; fit-for-purpose; glucagon-like peptide-1; immunoaffinity LC–MS; multilaboratory evaluation.

MeSH terms

  • Animals
  • Biomarkers
  • Chromatography, Liquid / methods
  • Glucagon-Like Peptide 1
  • Laboratories*
  • Rats
  • Tandem Mass Spectrometry* / methods

Substances

  • Glucagon-Like Peptide 1
  • Biomarkers